Differential effects of metoprolol and atenolol to neuropeptide Y blockade in coronary artery disease

What Was Tested

This randomized controlled trial paper looks at Neuropeptide Y.

To explore possible differential effects between metoprolol and atenolol in patients with coronary artery disease.

Who Took Part

PubMed indexes the participants as adults, middle-aged adults and older adults, men only.

Most patients were treated with metoprolol or atenolol.

In a post hoc analysis the researchers compared the hemodynamic response to exercise of the Y1 antagonist in patients on metoprolol (n = 16) and atenolol (n = 5), and assessed respiratory sinus arrhythmia (RSA), an indirect measurement of cardiac vagal activation, in the placebo phase in patients on metoprolol (n = 26) and on atenolol (n = 24).

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and crossover.

The participants were allocated by chance, so the Neuropeptide Y group and the comparison group should start out alike.

As a double-blind Neuropeptide Y study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of Neuropeptide Y, giving a reference point.

Each person switched between Neuropeptide Y and the comparison at some point, usually with a gap in between.

The study was randomized, double blind, two-way crossover with the Y1 antagonist AR-H040922 given as IV infusion for 2 h or placebo.

What Was Measured

The subject headings attached to it are Adrenergic beta-1 Receptor Antagonists, Angina, Stable, Atenolol, Blood Pressure, Coronary Artery Disease, Exercise and Heart Rate.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Neuropeptide Y.

Results are reported in around 2 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2012 (Scandinavian cardiovascular journal : SCJ), a journal based in England.

More context: the Neuropeptide Y compound page, all human trials.